Enliven Therapeutics
Boulder, United States · Biotechnology, Healthcare, Health Care
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from cl
Key facts
- Headquarters
- Boulder, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ELVN)
- Website
- www.enliventherapeutics.com
- Company page
Recent activity at Enliven Therapeutics
- : Enliven Therapeutics Appoints Kristine Ball as Class II Director
- : SEC 8-K (5.02): On October 14, 2026, Enliven Therapeutics, Inc. appointed Kristine Ball as a Class II director, increasing the board size from seven to eight members. Her term will expire at the Company’s 2028 annual meeting of stockholders, effective the same day. Ms. Ball will receive an annual cash compensation of $45,000 for serving as an outside director and an additional $10,000 for her role on the Audit Committee. She has been granted stock options with a fair value of approximately $650,000, which will vest monthly, subject to her continued service, and will fully vest in the event of a Change in Control. The Company also entered into its standard indemnification agreement with Ms. Ball.
- : SEC 8-K (1.01): On June 11, 2026, Enliven Therapeutics, Inc. entered into a Material Definitive Agreement through an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Barclays Capital Inc. The agreement pertains to the public offering of 8,933,334 shares of the Company's common stock at a public offering price of $37.50 per share, along with pre-funded warrants for an additional 1,733,333 shares. The Company is expected to raise approximately $376.0 million, or $432.4 million if the underwriters fully exercise their option. The offering is set to close on June 15, 2026, contingent on customary closing conditions. This strategic move anticipates enhancing the Company’s financial position significantly, with the proceeds aimed at advancing its business goals.
- : SEC 8-K (8.01): On June 11, 2026, the Company announced significant updates regarding the Phase 1 ENABLE clinical trial for its drug ELVN-001 targeting chronic myeloid leukemia (CML). As of the March 10, 2026 cutoff, 161 heavily pretreated patients were enrolled, with promising results showcasing a major molecular response (MMR) rate of 54% and a deep molecular response (DMR) rate of 22% by 24 weeks. Notably, the drug exhibited a safety profile consistent with high selectivity for ABL1, with only 6% of patients discontinuing due to adverse events. This robust outcome signifies a strategic advancement in the treatment landscape of CML, particularly for patients with a history of multiple prior therapies.
- : SEC 8-K (5.02): On January 6, 2026, Enliven Therapeutics, Inc. appointed Scott Garland as a Class I director and as Chair of the Nominating and Corporate Governance Committee, effective January 7, 2026. Mr. Garland has previously consulted for the Company, earning $314,650 and vesting options for 26,580 shares. He will receive annual compensation of $40,000 as a director and $10,000 as Chair, with stock options valued at approximately $650,000 that will vest monthly. Concurrently, Andrew Phillips, Ph.D., resigned from the Board and its committees, effective January 7, 2026, without disagreement over Company matters.
- : Enliven Appoints Rick Fair as Chief Executive Officer
- : SEC 8-K (5.02): On December 11, 2025, Enliven Therapeutics, Inc. announced the appointment of Richard Fair as the President and Chief Executive Officer and a member of the board of directors, effective immediately. Samuel Kintz is resigning from his role as President and Chief Executive Officer, transitioning to Head of Pipeline. Richard Fair brings over 25 years of experience, having previously served as CEO of Bellicum Pharmaceuticals and in leadership roles at Roche/Genentech and Johnson & Johnson. As part of his compensation package, Mr. Fair will receive an annual base salary of $660,000 and an eligibility for an annual bonus of up to 55% of his base salary, contingent on performance criteria set by the Board. The effective date of this appointment is significant as it reflects a leadership transition aimed at steering company strategy forward.
- : SEC 8-K (2.02): On November 12, 2025, Enliven Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The filing serves as Amendment No. 1 to a previous report, correcting the information in the press release attached as Exhibit 99.1. This event provides stakeholders with updated operational and financial performance metrics, reflects on the Company's quarterly performance, and outlines financial health and strategies moving forward. Such announcements are significant for investors and analysts to evaluate the company's market position and strategic direction.
- : Enliven Therapeutics
- : Enliven Therapeutics raised $90 million in a private placement financing to fund research and development of its clinical-stage product candidates.
Enliven Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2024 | Venture | $90.0M |
| Mar 2024 | Post-IPO Equity | $90.0M |
| Jan 2022 | Funding Round | Undisclosed |
| Mar 2019 | Venture | $44.1M |
| Apr 2016 | Venture | $6.0M |
Leadership
- Mark Chin, Director
- David Bonita, Director
- Sara Nayeem, Director
- David Mott, Director
- Carl Goldfischer, Director
- Barbara Dalton, Director
- James McArthur, Director
- Mette Agger, Director
- Rahul Ballal, Executive Officer, Director
- Sara Nayeem, Director
- David Mott, Director
- Barbara Dalton, Director
Verified email and direct lines for Enliven Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Enliven Therapeutics in the news
- Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire (Sep 03, 2026)
- Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire (Jun 11, 2026)
- Enliven Therapeutics, Inc. (ELVN) Company Profile & Facts - Yahoo! Finance Canada (Sep 08, 2024)
- Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire (Aug 31, 2026)
- Enliven Therapeutics, Inc. (ELVN) stock price, news, quote and history - Yahoo Finance Australia (Mar 22, 2024)
- Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire (Jun 13, 2025)
Companies similar to Enliven Therapeutics
- ADARx Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care, Therapeutics
About Enliven Therapeutics: questions and answers
What does Enliven Therapeutics do?
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from cl
Where is Enliven Therapeutics headquartered?
Enliven Therapeutics is headquartered in Boulder, United States.
Has Enliven Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Enliven Therapeutics. The most recent, $90.0M, was in Apr 2024.
What is the latest news on Enliven Therapeutics?
On Oct 14, 2026, Enliven Therapeutics Appoints Kristine Ball as Class II Director
Is Enliven Therapeutics a public company?
Yes. Enliven Therapeutics is publicly traded under the ticker ELVN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy